ELV · Financials · Insurer · FY2025 filings ·
Scored by the financial-sector model
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for ELV.
Flagship explainer
ELEVANCE HEALTH, INC.'s filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:
| Filed line | Value | % of net interest income | Source |
|---|---|---|---|
| Income before tax | $6.7B | Unavailable |
|
| Income tax | $1.0B | Unavailable |
|
| $5.7B | Unavailable |
|
Flagship explainer
The filed balance sheet is shown without an invented “other” bucket.
Honest partial: the filing did not provide a normalized tag for Non-current assets, Receivables, Inventory, Capitalized contract costs, Non-current liabilities, Accounts payable; those components are omitted, not plugged.
| Filed line | Value | % of assets | Source |
|---|---|---|---|
| Total assets | $121.5B | 100% |
|
| Current assets | $63.0B | 52% |
|
| Cash and equivalents | $9.5B | 8% |
|
| Property, plant and equipment | $4.7B | 4% |
|
| Goodwill | $28.3B | 23% |
|
| Other intangible assets | $11.2B | 9% |
|
| Deferred tax assets | $2.1B | 2% |
|
| Other non-current assets | $2.3B | 2% |
|
| Operating lease right-of-use assets | $452M | 0% |
|
| Total liabilities | $77.5B | 64% |
|
| Current liabilities | $41.0B | 34% |
|
| $32.0B | 26% |
| |
| Stockholders’ equity | $43.9B | 36% |
|
Flagship explainer
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $5.7B | FY2025 |
| |
| Income before tax | $6.7B | FY2025 |
|
| Operating income | $7.2B | FY2025 |
|
| $199.1B | FY2025 |
| |
| Ending assets | $121.5B | FY2025 |
|
| Beginning assets | $116.9B | FY2024 |
|
| $43.9B | FY2025 |
| |
| $41.3B | FY2024 |
|
Flagship explainer
ELEVANCE HEALTH, INC.’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:
| Filed line | Value | % of cash from operations | Source |
|---|---|---|---|
| Cash from operations | $4.3B | 100% |
|
| Depreciation and amortization | $1.5B | 36% |
|
| Share-based compensation | $276M | 6% |
|
| Cash from investing | −$1.3B | −31% |
|
| Cash from financing | −$1.7B | −41% |
|
| Exchange-rate effect | −$5M | −0% |
|
| Net change in cash | $1.2B | 28% |
|
Curated 19-manager tier
Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.
1 holding0 exited10 not holding11/19 resolved8 not retrieved
| Manager | Reported position | Quarter-over-quarter | Filing accession |
|---|---|---|---|
| Oakmark / Harris Associates | 4,924,511 shares$1.9B · 3% of eligible reported 13F | Added to position · +127,985 shares (3%) |
|
| Abrams Capital | No position reported | No position reported |
|
| Akre Capital | No position reported | No position reported |
|
| Berkshire Hathaway | No position reported | No position reported |
|
| Fundsmith | No position reported | No position reported |
|
| Gardner Russo & Quinn | No position reported | No position reported |
|
| Gates Foundation Trust | No position reported | No position reported |
|
| Mairs & Power | No position reported | No position reported |
|
| Markel / Markel-Gayner | No position reported | No position reported |
|
| Polen Capital | No position reported | No position reported |
|
| Southeastern Asset Management | No position reported | No position reported |
|
| Baupost Group | Not retrieved | Comparison not retrieved | Filing not retrieved |
| Brave Warrior Advisors | Not retrieved | Comparison not retrieved | Filing not retrieved |
| Dodge & Cox | Not retrieved | Comparison not retrieved | Filing not retrieved |
| First Eagle | Not retrieved | Comparison not retrieved | Filing not retrieved |
| Pershing Square | Not retrieved | Comparison not retrieved | Filing not retrieved |
| Sequoia / Ruane Cunniff | Not retrieved | Comparison not retrieved | Filing not retrieved |
| Tweedy, Browne | Not retrieved | Comparison not retrieved | Filing not retrieved |
| Yacktman Asset Management | Not retrieved | Comparison not retrieved | Filing not retrieved |
Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.
Flagship explainer
We could not retrieve insider activity for this rendering; no zero-activity claim is shown.
Unavailable: Form 4 activity could not be retrieved for this rendering.
Median ROE 14.9% on average equity, above the 10% hurdle in 100% of 9 years.
Q3 scored 2 evidenced ratios equally.
Profitable in 100% of 10 years, ROE very steady.
Not scored for this company
Scored 3 of 4 applicable components (carrier model); weights renormalized over the scored set.
The 15-year revenue, margin, and ROIC series is built for the operating model’s lens and isn’t published for banks and insurers — a balance-sheet business is read through the components above, not through operating-company margins.
| Reading | ||
|---|---|---|
| Aug 3, 2026 | 94 | |
| Jul 26, 2026 | 93 | |
| Jul 26, 2026 | 93 | |
Append-only — readings are added, never rewritten. Only readings on the same methodology version (moat-index-financials@1.0.0) are comparable; a change across versions is a scoring change, not a company event.